Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...

The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043SAN DIEGO, April 23, 2025 ...

More information: Monica Gobran et al, PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division, The EMBO Journal (2025). DOI: 10.1038 ...

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

Erroneous or uncontrolled cell division can have serious consequences, leading to diseases such as cancer. Plk1 plays a key role in this regulatory process. It activates other proteins involved in ...

Plk1, a protein kinase, plays a crucial role in regulating the timing of cell division by acting as a molecular switch. Inhibiting Plk1 delays the onset of cell division, keeping cells in the ...

Onvansertib, a PLK1 inhibitor, is currently being evaluated in a first-line Phase 2, randomized, open-label trial (CRDF-004) in combination with FOLFIRI and bev or FOLFOX and bev for the treatment of ...